You are here : Home > BCI Laboratory > An innovative approach to inhibit CK2 protein kinase

highlight / actuality

An innovative approach to inhibit CK2 protein kinase


Following a chemical screen, researchers at the laboratory characterized two molecules that behave in vitro as antagonists of the CK2α/CK2ß interaction. They disrupt CK2-dependent signaling in cultured cells and lead to inhibition of proliferation and induction of apoptosis of mammary cancer cells. Selective inhibition of the CK2α/CK2ß interaction therefore represents an innovative approach that offers the possibility of pharmacologically testing the importance of this interaction in tumor growth processes.

Published on 31 October 2019
Highlight available in French.

Top page